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Correlation Between Chlamydia pneumoniae Detection From
and Atherosclerosis Severityo the Editor: The relevance of Chlamydia pneumoniae (Cpn) in
therosclerosis is debated (1). Reliable diagnostic tests for endovascu-
ar bacteria require biopsies during atherectomy or bypass surgery.
hey are performed at advanced stages of atherosclerosis and are not
uitable for exploring if Chlamydia infection is an additional risk
actor. We developed a new diagnostic approach to detect endocoro-
ary bacteria. We extracted DNA from balloons after dilatation,
etected Cpn by polymerase chain reaction (PCR), and correlated
mplification results with coronary artery disease (CAD) severity.
We prospectively studied 101 unselected patients. Symptomatic CAD
as acute coronary syndrome or stable angina. Asymptomatic CADwas
ilent ischemia related to hemodynamically significant stenosis.
Washed balloon catheters were cut off and frozen in 180 l ATL
uffer (DNA Mini Kit tissue; Qiagen, Courtaboeuf, France). Pro-
einase K (20 l) was added; the sample was vortexed and lysed (1 h,
6°C); 180 l was used as sample, and 20 l was added to 160 l
hosphate-buffered saline as positive control: 1 l plasmid DNA
olution was added, containing 100 copies/l of a 487-bp fragment of
heMOMP gene (Cpn0695), cloned using APN1 and APN2 primers
2) into the pGEM-T vector (Promega, Charbonnie`res, France). The
rocedure followed the manufacturer’s instructions.
A nested PCR protocol, taking care to avoid contaminations
3), was performed using a Perkin-Elmer (Courtaboeuf, France)
hermal cycler. Primers were APN1 and APN2, and for the second
ound they were 5=CTACTGGAACAAAGTCTGCG3= and
=CAGATACGTGAGCAGCTCTC3=.
Cycle conditions were: 5 min at 94°C, 35 cycles of 30 s at 94°C,
0 s annealing at 55°C, 60 s at 72°C, and final extension 7 min at
2°C. In the second amplification, annealing was at 50°C. Ampli-
ons appeared as a 390-bp product on agarose gels. Every balloon
as studied in triplicate with positive and negative controls. The
CR allowed detection of ten copies of bacterial DNA per tube.
Potential associations between patient data and CAD severity
ere tested by univariate procedures using Student t tests for ageMultivariate analysis relied upon stepwise logistic regression.
ariables with p  0.10 in univariate analysis were included in the
odel. The p values were two-sided, and values of 0.05 were
onsidered significant. Analyses were performed with the SAS 8.2
oftware (SAS Institute, Cary, North Carolina).
We examined the presence of Cpn DNA in balloons from 101
atients. Nine were excluded from analysis for technical reasons:
able 1. Clinical and Angiographic Characteristics of Patients
Atherosclerosis
(n  76)
Restenosis
(n  11)
ge, yrs 65 (11.4) 61 (6.4)
ale gender 60 (79%) 11 (100%)
isk factors
Diabetes mellitus 18 (24) 3 (27)
Systemic hypertension 39 (51) 6 (55)
Hypercholesterolemia 42 (55) 7 (64)
Smoking 37 (49) 7 (64)
Familial history of CAD 12 (16) 4 (36)
edical history
Previous CAD* 32 (42) 11 (100)
Previous coronary
angioplasty
18 (24) 11 (100)
Previous CABG 4 (6) 1 (9)
linical status
Asymptomatic CAD 26 (34) 5 (45)
Symptomatic CAD 50 (66) 6 (55)
essels involved
1 28 (37) 4 (36)
2 48 (63) 7 (64)
. pneumoniae PCR-
positive patients,
n (% [95% CI])
30 (39.5% [28.4–51.4]) 0 (0% [0–28.5])
alues are n (%); age is the mean value (SD). *Myocardial infarction1 month, acute
oronary syndrome, moderate to severe stable angina, percutaneous coronary inter-
ention, or coronary artery bypass graft.
CAD  coronary artery disease; CABG  coronary artery bypass graft; CI 
onfidence interval; PCR  polymerase chain reaction.
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March 21, 2006:1226–38resence of PCR inhibitors (n  3) and accidental contamination (n
6). Five were excluded for medical reasons: coexisting restenotic
nd atherosclerotic lesions (n 2), occluded lesions that could not be
rossed (n  2), and rejection after cardiac transplantation (n  1).
The clinical and angiographic data of the 87 remaining patients are
ummarized in Table 1. Except for clinical history, the 76 patients
ith atherosclerosis and the 11 patients with restenosis were similar
or risk factors, clinical status, and number of diseased vessels.
We analyzed 204 balloons: 176 from atherosclerotic and 28
rom restenotic patients. The mean number of balloons studied per
atient was about 2.5 in both groups. Thirty (39.5% [95%
onfidence interval (CI): 28.4 to 51.4]) of the 76 patients treated
or primary stenosis were PCR positive, compared with none (0%
95% CI: 0 to 28.5]) of the 11 patients with restenosis (p  0.01).
Table 2 shows the clinical and angiographic characteristics of
he patients treated for native atherosclerosis. Main risk factors
ere similar in both groups. The PCR-positive patients reported a
amilial history of CADmore often (p 0.05), suffered from more
evere CAD, and had significantly more frequent personal history
f coronary events (i.e., myocardial infarction 1 month, acute
oronary syndrome, stable angina, or revascularization procedures)
63.3% vs. 28.3%; p  0.003), symptomatic CAD (80% vs. 56.5%;
 0.04), and multivessel disease at angiography (80% vs. 52.2%;
 0.01) than PCR-negative patients.
We examined whether Cpn was independently associated with
ymptomatic CAD and multivessel disease by studying the follow-
ng in univariate analyses: age, gender, diabetes, hypertension,
ypercholesterolemia, smoking, CAD familial history, medical
istory, and positive PCR. In univariate analyses, positive PCR
nd diabetes were associated with symptomatic CAD. Multivariate
nalyses showed that only detection of Cpn by PCR was positively
ssociated with symptomatic CAD (odds ratio 4.04 [95% CI: 1.23
o 13.28]; p  0.021). However, and not unexpectedly, diabetes
as negatively correlated (odds ratio 0.17 [95% CI: 0.05 to 0.59];
 0.005) with the existence of coronary symptoms.
Smoking status and positive PCR were positively associated
ith multivessel disease in univariate analysis. In multivariate
able 2. PCR Results in the 76 Patients With Atherosclerotic
esions
PCR 
(n  30)
PCR 
(n  46) p Value
ge, mean (SD) 66 (12.4) 65 (10.2) 0.7
ale gender, % 87 72 0.13
isk factors, %
Diabetes mellitus 26.7 21.7 0.6
Systemic hypertension 46.7 54.3 0.5
Hypercholesterolemia 53.3 56.5 0.8
Smoking 53.3 45.7 0.5
Familial history of CAD 26.7 8.7 0.05
edical history, %
Previous angioplasty or CABG 41.4 22.2 0.08
Previous CAD* 63.3 28.3 0.003
linical status, %
Asymptomatic CAD 20.0 43.5
Symptomatic CAD 80.0 56.5 0.04
essels involved, %
1 20 47.8
2 80 52.2 0.01
bbreviations and notes as in Table 1.nalysis, positive PCR was the only variable significantly associated
1ith multivessel disease (odds ratio 3.67 [95% CI: 1.26 to 10.64];
 0.017).
In conclusion, we report on the first assessment of angio-
lasty balloons to detect bacteria in coronary artery lesions.
hlamydia pneumoniae DNA was detected in 39.5% of patients
ith native atherosclerotic stenosis. An overview of 43 studies
nalyzing 2,679 atherosclerotic lesions removed at autopsy or
uring surgery or atherectomy reported a bacterial detection rate of
4% by PCR amplification and of 48% by immunohistochemistry
3). However, the true prevalence is unknown as detection rates
aried between investigators.
To standardize the procedure, we used a plasmid as internal
CR quality control, which ensured a threshold of 10 bacteria/
ube. Thus, negative results do not mean that the ChlamydiaDNA
as absent but rather below this threshold. Negative controls were
atients with restenotic lesions, mostly because of in-stent reste-
osis, resulting from the formation of a neointima different from
ative atherosclerosis. If contaminations had occurred, experimen-
ally or from circulating bacteria, these balloons should have been
s often positive as those of atherosclerotic patients.
Chlamydia serology was not performed because numerous stud-
es have shown major limitations (4,5).
We showed that Chlamydia pneumoniae is associated with:
) clinical CAD severity; 2) multivessel disease; and 3) native
therosclerosis. The association between Chlamydia detection and
oronary lesion severity, independently of the main risk factors,
trengthens infection as an atherosclerosis risk factor. Our diag-
ostic tool could help target therapeutic trials on patients with
ndovascular bacteria at earlier atherosclerosis stages than in
revious studies. It could also allow assessing a putative relation-
hip between Cpn presence and atherosclerosis progression.
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Decline in C-Reactive Protein After Successful Ablation of Long-Lasting
Fibrillationo the Editor: Increased levels of C-reactive protein (CRP) have
een demonstrated to be an independent predictor of atrial fibrillation
AF) and to correlate with AF burden (1,2). In addition, inflam-
ation and endothelial activation have been described as risk
actors for adverse events in AF (3,4).
Whether inflammation and endothelial dysfunction are a cause
r a consequence of AF remains unknown. Development of CRP
evels after cardioversion of AF has shown controversial results,
nd data on evolution of inflammation after ablation are lacking.
This study investigated whether elimination of AF by ablation
ould influence the inflammatory state and endothelial dysfunction.
Fifty consecutive patients (49 males, 1 female; age 53  10
ears) referred for ablation of persistent or permanent drug-
efractory AF were studied. Five patients had long-lasting persis-
ent AF, defined as episodes lasting 7 days (mean 6 months,
ange 3 to 10 months). Forty-five patients suffered from perma-
ent AF, defined as AF that failed cardioversion or lasted for 1
ear. Atrial fibrillation was persisting for a median of 24 months
range 2 months to 20 years).
The ablation procedure was described in detail elsewhere (5).
ll patients underwent pulmonary vein isolation (PVI). Further
ubstrate modification consisted of linear lesions at the mitral
sthmus and at the roof of the left atrium. In patients with ongoing
F after PVI and linear ablation the following additional steps
ere performed: 1) energy applications at sites showing rapid or
eterogeneous activity for 90 to 120 s; 2) an intercaval line joining
he superior and inferior caval vein at their posterior aspect; and
) cardioversion.
A detailed data form including preclinical and procedural data
as completed for every patient. At the follow-up examinations
after 1 and 3 months) clinical symptoms were evaluated and
ransthoracic echocardiography and a 48-h electrocardiogram
ECG) performed. Follow-up blood samples were taken at the
-month follow-up. Patients suffering from any tachyarrhythmia
ymptoms or showing any atrial arrhythmia on 48-h ECG were
lassified as having recurrent arrhythmia. All antiarrhythmics
emained unchanged for at least 3 months after the index proce-
ure, as did all other medications, including anticoagulants,
eta-blockers, statins, angiotensin-converting enzyme (ACE) in-
ibitors and angiotensin (AT) II antagonists.
Plasma samples were frozen at 70°C and stored for further
xamination. All paired blood samples were analyzed on the same
ay to avoid calibration errors. High-sensitivity CRP (hsCRP) and
on Willebrand factor (vWf) activity were measured using com-
ercially available testing kits (hsCRP: BNII analyzer; Dade
ehring., Paris, France; vWf: Asserachrom vWf; Diagnosticahe hsCRP assay has a typical detection limit at 0.155 mg/l.
ormal activity for the Asserachrom vWf assay ranges from 50%
o 150%.
Fifteen patients (30%) suffered from structural heart disease.
ourteen patients were taking amiodarone at the time of the
rocedure, 11 patients were taking ACE inhibitors or AT II
ntagonists, 4 patients were taking statins, and 3 patients were
aking aspirin. Twenty-five patients were treated with beta-
lockers, which were stopped at least five half-lives before the
rocedure. Mean baseline hsCRP was 2.66 mg/l (range 0.155 to
3.9 mg/l), and mean vWf activity was 132 50%. There were no
ifferences in baseline characteristics for patients with successful
blation or failed maintenance of sinus rhythm 3 months after
blation (Table 1).
All patients underwent a single procedure after collection of
aseline data. At 3-month follow-up, 33 patients (66%) were free
f arrhythmia, 17 patients (34%) failed to maintain sinus rhythm,
2 suffered from paroxysmal AF, and 5 suffered from atrial
achycardia. Left atrial parasternal diameter decreased significantly
n the successfully treated group (45.8  5.6 mm vs. 42.6  4.8
m; p  0.003 by t test) but showed no change in the group with
ngoing arrhythmia (45.2 7.7 mm vs. 45.4 5.3 mm; p 0.9).
eft ventricular diameters and LVEF showed no difference before
nd after ablation in either group. Both groups had comparable
umulative radiofrequency energy delivery (87  32 min vs. 79 
0 min; p  0.5).
At baseline there was no difference in CRP between the
uccessfully treated patients and the patients with ongoing arrhyth-
ia (2.82  3.1 mg/l vs. 2.46  3.6 mg/l; p  0.32). At three
onths, CRP declined significantly in successfully treated patients
able 1. Baseline Patients Characteristics
Success
(n  33)
Failure
(n  17)
p
Value
ge (yrs) 53  10 54  10 0.7
F duration (months) 24 (3–96) 24 (12–60) 0.5
tructural heart disease 9 3 0.7
miodarone 9 5 0.9
tatin medication 2 2 0.6
spirin medication 2 1 0.6
igh-sensitivity CRP (mg/l) 2.82  3.1 2.46  3.6 0.3
Wf activity (%) 128  48 136  30 0.7
reatinine (mol/l) 92  12 94  16 0.7
eft atrial parasternal diameter (mm) 46  6 45  8 0.7
VEF (%) 65  11 62  11 0.5
adiofrequency duration (min) 87  32 79  30 0.5F  atrial fibrillation; CRP  C-reactive protein; vWf  von Willebrand factor;
VEF  left ventricular ejection fraction.
